Viking NASH

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess The Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

Location: CPMC (San Francisco)

Please contact: clinicalresearch@sutterhealth.org about study Viking NASH 

Principal Investigator

Edward Holt, MD

Co-Investigator(s)

Kidist Yimam, MD, Todd Frederick, M.D., Raphael Merriman, MD 

Recruitment Status

Active, Recruiting